Medicines: packaging, labelling and patient information leaflets

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines mandatory standards for the labeling and packaging of medicinal products for all Marketing Authorisation holders. Operating under The Human Medicines Regulation 2012 and the Windsor Framework, the agency emphasizes patient safety through clear communication and physical safeguards. Key requirements include the mandatory inclusion of Braille for product names, the prohibition of over-labeling, and the implementation of child-resistant packaging for products containing paracetamol, aspirin, or specific iron levels. A significant regulatory shift occurs on January 1, 2025, after which joint packs with other countries are prohibited; all medicines must feature UK-specific outer cartons labeled 'UK Only.' Patient Information Leaflets (PILs) must be easy to read and strictly exclude personal staff data to maintain privacy. To ensure compliance, companies must submit packaging changes via a notification scheme or a full assessment process depending on the nature of the update. Following MHRA approval, companies are generally required to implement changes within three to six months. The MHRA actively investigates complaints regarding non-compliance, requiring manufacturers to respond to identified safety issues within seven days. Failure to adhere to these standards, such as using incorrect child-resistant materials or outdated multi-market packaging, may result in regulatory action or required variations to existing licenses.